Rigel Pharmaceuticals

RIGL · United States

Share price · RIGL

$42.53-1.09 (-2.50%) 3M

close as of 2026-11-18 · 24h delayed · vol 305K (1.3x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when RIGL's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 10 Nov 2026+4.4%
  2. 6 Nov 2026-13.3%
  3. 5 Nov 2026-10.9%
  4. 3 Nov 2026-3.3%
  5. 7 Oct 2026+4.1%
  6. 14 Sep 2026-4.0%
  7. 14 Aug 2026+4.4%
  8. 22 Jun 2026+8.6%
  9. 13 May 2026+9.4%
  10. 12 May 2026+12.1%

Share of unusual movement by asset

For each asset, the share of RIGL's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Vepdegestrant (Veppanu)
events and moves
6shown from 8 days
Olutasidenib
events and moves
3shown from 8 days
fostamatinib (Tavalisse)
events and moves
3shown from 8 days
Pralsetinib
events and moves
3shown from 8 days
Assets with fewer than 8 event days, together—4%
Other company news (earnings, financing, releases naming no asset)—53%
Sessions with no dated event—43%

Assets

(5 total)
5Total Assets
4Approved
0Phase 3 / Filed
1Phase 1–2 / Early
6Diseases
Quick filter:
Showing 5 of 5 assets
Target & Modality
fostamatinib(Tavalisse)
Approved
Spleen tyrosine kinase (Syk)Small molecule
Immune Thrombocytopenia
Approved
Mutant IDH1Small molecule
Acute Myeloid LeukemiaGlioma
Relapsed/Refractory Acute Myeloid Leukemia
Approved
RETSmall molecule
Non-Small Cell Lung Cancer
Vepdegestrant(Veppanu)
Approved
Estrogen receptorSmall molecule
Breast Cancer
HR+/HER2- Metastatic Breast Cancer
Phase 1/2
IRAK1/IRAK4Small molecule
Myelodysplastic Syndromes

Upcoming events

(6 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
Vepdegestrant · VeppanuPhase 3Breast Cancer
Est. primary completion 2026-12-30 · NCT05909397 · CT.gov ↗
What to watch
2027 (2)
March 2027 (1)
Vepdegestrant · VeppanuPhase 1/2Breast Cancer
Est. primary completion 2027-03-24 · NCT05548127 · CT.gov ↗
What to watch
December 2027 (1)
R289Phase 1/2Low Risk Myelodysplastic Syndromes
Est. primary completion 2027-12 · NCT05308264 · CT.gov ↗
What to watch
2029 (2)
June 2029 (1)
OlutasidenibPhase 2High Grade Glioma, Astrocytoma, Astrocytoma, Grade III, Astrocytoma, Grade IV, Diffuse Intrinsic Pontine Glioma, WHO Grade III Glioma …
Est. primary completion 2029-06 · NCT06161974 · CT.gov ↗
What to watch
August 2029 (1)
Vepdegestrant · VeppanuPhase 2Locally Advanced or Metastatic ER+ HER2- Breast Cancer, Locally Advanced or Metastatic Castration-resistant Prostate Cancer …
Est. primary completion 2029-08-27 · NCT04606446 · CT.gov ↗
What to watch
2030 (1)
September 2030 (1)
OlutasidenibPhase 2Relapsed or Refractory IDH1 Mutation-Positive Acute Myeloid Leukemia
Est. primary completion 2030-09 · NCT07604064 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(4)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

1 May 2026ApprovalVepdegestrantFDA approves VEPPANU (vepdegestrant)
US, FDA · Arvinas · Source ↗
December 2025ApprovalPralsetinibFDA updates Boxed Warning on Pralsetinib (NDA213721)
US, FDA · FDA · Source ↗
8 August 2025Filing acceptedVepdegestrantFDA accepts vepdegestrant NDA
US, FDA · Arvinas · Source ↗
11 March 2025Topline resultVepdegestrantVERITAC-2 Phase 3 topline results
Arvinas · Source ↗

Financial reports

Quarterly & interim (16)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3$81M$18M$47M+ $53M short-term inv.—$35M operating cash flowreport ↗
View 15 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2$79M—$61M+ $35M short-term inv.—$31M operating cash flowreport ↗
2026-Q1$59M—$24M+ $122M short-term inv.—$2.7M operating cash flowreport ↗
2025-Q3$69M$7.3M$49M+ $89M short-term inv.—$24M operating cash flowreport ↗
2025-Q2$102M$6.8M$53M+ $55M short-term inv.—$31M operating cash flowreport ↗
2025-Q1$53M$8.4M$46M+ $31M short-term inv.—-$0.9M operating cash flowreport ↗
2024-Q3$55M$6.2M$52M+ $9.4M short-term inv.—$22M operating cash flowreport ↗
2024-Q2$37M$5.5M$36M+ $13M short-term inv.$1.0M$0.3M operating cash flowreport ↗
2024-Q1$30M$6.0M$26M+ $24M short-term inv.$8.3M-$5.0M operating cash flowreport ↗
2023-Q3$28M$6.5M$45M+ $17M short-term inv.$5.7M-$1.4M operating cash flowreport ↗
2023-Q2$27M$4.8M$49M+ $16M short-term inv.$6.6M$5.9M operating cash flowreport ↗
2023-Q1$26M$10M$40M+ $18M short-term inv.$14M-$4.1M operating cash flowreport ↗
2022-Q3$22M$15M$30M+ $52M short-term inv.$19M-$13M operating cash flowreport ↗
2022-Q2$30M$15M$27M+ $62M short-term inv.$13M-$13M operating cash flowreport ↗
2022-Q1$17M$15M$25M+ $83M short-term inv.$27M-$26M operating cash flowreport ↗
2021-Q3$22M$18M$30M+ $113M short-term inv.$21M-$10M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$294M—$41M+ $114M short-term inv.—$76M operating cash flowreport ↗

Rigel reported full-year 2025 total revenues of $294.28M, up 64.1% YoY, with net product sales of $232.0M and contract revenues of $62.3M. R&D expense was $33.295M, and cash, cash equivalents and short-term investments were $155.0M at year-end. The company reported net income of $367.0M for the full year, including a $245.9M non-cash deferred income tax benefit; fourth-quarter net income was $268.1M.

Rigel guided to 2026 total revenues of approximately $275–$290M, including net product sales of $255–$265M and contract revenues of $20–$25M, with positive full-year net income. Clinically, enrollment is ongoing in the dose expansion phase of the Phase 1b study of R289 in lower-risk MDS, with completion and recommended Phase 2 dose selection expected in the second half of 2026 and preliminary data anticipated by end of 2026; updated R289 dose-escalation data were presented at ASH 2025. The company also presented olutasidenib data at ASH, enrolled the first patient in the CONNECT Phase 2 TarGeT-D study, presented pralsetinib data at NACLC and ASCO-GI, received FDA approval of a GAVRETO labeling update adding a boxed warning about serious infections, published five-year olutasidenib results, and added Michael P. Miller to its board of directors.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$179M$23M$57M+ $21M short-term inv.—$31M operating cash flowreport ↗
2023-FY$117M$25M$33M+ $24M short-term inv.$6.3M-$5.7M operating cash flowreport ↗
2022-FY$120M$60M$24M+ $34M short-term inv.$15M-$74M operating cash flowreport ↗
2021-FY$149M$65M$19M+ $106M short-term inv.$4.5M$5.9M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 0 purchases ($0), 3 sales ($306K). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-09-02Schorno Dean L · EVP & Chief Financial OfficerOption exercise694$12.70$9KForm 4
2026-09-02Schorno Dean L · EVP & Chief Financial OfficerOption exercise620$18.70$12KForm 4
2026-09-02Schorno Dean L · EVP & Chief Financial OfficerOption exercise2,000$24.20$48KForm 4
2026-09-02Schorno Dean L · EVP & Chief Financial OfficerOption exercise1,286$24.20$31KForm 4
2026-09-02Schorno Dean L · EVP & Chief Financial OfficerOption exercise (derivative)694——Form 4
2026-09-02Schorno Dean L · EVP & Chief Financial OfficerOption exercise (derivative)620——Form 4
2026-09-02Schorno Dean L · EVP & Chief Financial OfficerOption exercise (derivative)2,000——Form 4
2026-09-02Schorno Dean L · EVP & Chief Financial OfficerOption exercise (derivative)1,286——Form 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 148 reporting institutions held 15.9M shares ($394.0M, 84.4% of shares outstanding).

#InstitutionSharesValue
1BlackRock, Inc.1,768,907$47.8M
2ARMISTICE CAPITAL, LLC1,280,000$34.6M
3STATE STREET CORP1,120,238$30.3M
4VANGUARD CAPITAL MANAGEMENT LLC764,193$20.7M
5MARSHALL WACE, LLP598,378$16.2M
6AMERICAN CENTURY COMPANIES INC544,431$14.7M
7D. E. Shaw & Co., Inc.445,678$12.1M
8GEODE CAPITAL MANAGEMENT, LLC440,626$11.9M
9GOLDMAN SACHS GROUP INC439,101$11.9M
10TWO SIGMA INVESTMENTS, LP405,807$11.0M
11DIMENSIONAL FUND ADVISORS LP379,541$10.3M
12Qube Research & Technologies Ltd343,897$9.3M
13RENAISSANCE TECHNOLOGIES LLC338,441$9.2M
14Nuveen, LLC337,427$9.1M
15MILLENNIUM MANAGEMENT LLC264,410$7.1M